Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
Conditions
- B Cell Lymphoma
- Acute Lymphoblastic Leukemia
Interventions
- GENETIC: Third generation CAR-T cells
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators